Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates
COVID-19 vaccines are being developed urgently worldwide. Here, we constructed two adenovirus vectored COVID-19 vaccine candidates of Sad23L-nCoV-S and Ad49L-nCoV-S carrying the full-length gene of SARS-CoV-2 spike protein. The immunogenicity of two vaccines was individually evaluated in mice. Speci...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-01-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2021.1931466 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849312888053825536 |
|---|---|
| author | Shengxue Luo Panli Zhang Bochao Liu Chan Yang Chaolan Liang Qi Wang Ling Zhang Xi Tang Jinfeng Li Shuiping Hou Jinfeng Zeng Yongshui Fu Jean-Pierre Allain Tingting Li Yuming Zhang Chengyao Li |
| author_facet | Shengxue Luo Panli Zhang Bochao Liu Chan Yang Chaolan Liang Qi Wang Ling Zhang Xi Tang Jinfeng Li Shuiping Hou Jinfeng Zeng Yongshui Fu Jean-Pierre Allain Tingting Li Yuming Zhang Chengyao Li |
| author_sort | Shengxue Luo |
| collection | DOAJ |
| description | COVID-19 vaccines are being developed urgently worldwide. Here, we constructed two adenovirus vectored COVID-19 vaccine candidates of Sad23L-nCoV-S and Ad49L-nCoV-S carrying the full-length gene of SARS-CoV-2 spike protein. The immunogenicity of two vaccines was individually evaluated in mice. Specific immune responses were observed by priming in a dose-dependent manner, and stronger responses were obtained by boosting. Furthermore, five rhesus macaques were primed with 5 × 109 PFU Sad23L-nCoV-S, followed by boosting with 5 × 109 PFU Ad49L-nCoV-S at 4-week interval. Both mice and macaques well tolerated the vaccine inoculations without detectable clinical or pathologic changes. In macaques, prime-boost regimen induced high titers of 103.16 anti-S, 102.75 anti-RBD binding antibody and 102.38 pseudovirus neutralizing antibody (pNAb) at 2 months, while pNAb decreased gradually to 101.45 at 7 months post-priming. Robust T-cell response of IFN-γ (712.6 SFCs/106 cells), IL-2 (334 SFCs/106 cells) and intracellular IFN-γ in CD4+/CD8+ T cell (0.39%/0.55%) to S peptides were detected in vaccinated macaques. It was concluded that prime-boost immunization with Sad23L-nCoV-S and Ad49L-nCoV-S can safely elicit strong immunity in animals in preparation of clinical phase 1/2 trials. |
| format | Article |
| id | doaj-art-721561afdda449f1a4fff8d6dd73280b |
| institution | Kabale University |
| issn | 2222-1751 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj-art-721561afdda449f1a4fff8d6dd73280b2025-08-20T03:52:56ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512021-01-011011002101510.1080/22221751.2021.1931466Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidatesShengxue Luo0Panli Zhang1Bochao Liu2Chan Yang3Chaolan Liang4Qi Wang5Ling Zhang6Xi Tang7Jinfeng Li8Shuiping Hou9Jinfeng Zeng10Yongshui Fu11Jean-Pierre Allain12Tingting Li13Yuming Zhang14Chengyao Li15Department of Pediatrics, Shenzhen Hospital, Southern Medical University, Shenzhen, People’s Republic of ChinaDepartment of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People’s Republic of ChinaDepartment of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People’s Republic of ChinaSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou, People’s Republic of ChinaDepartment of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People’s Republic of ChinaDepartment of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People’s Republic of ChinaDepartment of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People’s Republic of ChinaDepartment of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People’s Republic of ChinaDepartment of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People’s Republic of ChinaDepartment of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People’s Republic of ChinaShenzhen Blood Center, Shenzhen, People’s Republic of ChinaDepartment of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People’s Republic of ChinaDepartment of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People’s Republic of ChinaDepartment of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People’s Republic of ChinaDepartment of Pediatrics, Shenzhen Hospital, Southern Medical University, Shenzhen, People’s Republic of ChinaDepartment of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People’s Republic of ChinaCOVID-19 vaccines are being developed urgently worldwide. Here, we constructed two adenovirus vectored COVID-19 vaccine candidates of Sad23L-nCoV-S and Ad49L-nCoV-S carrying the full-length gene of SARS-CoV-2 spike protein. The immunogenicity of two vaccines was individually evaluated in mice. Specific immune responses were observed by priming in a dose-dependent manner, and stronger responses were obtained by boosting. Furthermore, five rhesus macaques were primed with 5 × 109 PFU Sad23L-nCoV-S, followed by boosting with 5 × 109 PFU Ad49L-nCoV-S at 4-week interval. Both mice and macaques well tolerated the vaccine inoculations without detectable clinical or pathologic changes. In macaques, prime-boost regimen induced high titers of 103.16 anti-S, 102.75 anti-RBD binding antibody and 102.38 pseudovirus neutralizing antibody (pNAb) at 2 months, while pNAb decreased gradually to 101.45 at 7 months post-priming. Robust T-cell response of IFN-γ (712.6 SFCs/106 cells), IL-2 (334 SFCs/106 cells) and intracellular IFN-γ in CD4+/CD8+ T cell (0.39%/0.55%) to S peptides were detected in vaccinated macaques. It was concluded that prime-boost immunization with Sad23L-nCoV-S and Ad49L-nCoV-S can safely elicit strong immunity in animals in preparation of clinical phase 1/2 trials.https://www.tandfonline.com/doi/10.1080/22221751.2021.1931466COVID-19 vaccinessimian adenovirus 23 vectorhuman adenovirus 49 vectorprime-boost vaccinationmice and non-human primates |
| spellingShingle | Shengxue Luo Panli Zhang Bochao Liu Chan Yang Chaolan Liang Qi Wang Ling Zhang Xi Tang Jinfeng Li Shuiping Hou Jinfeng Zeng Yongshui Fu Jean-Pierre Allain Tingting Li Yuming Zhang Chengyao Li Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates Emerging Microbes and Infections COVID-19 vaccines simian adenovirus 23 vector human adenovirus 49 vector prime-boost vaccination mice and non-human primates |
| title | Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates |
| title_full | Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates |
| title_fullStr | Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates |
| title_full_unstemmed | Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates |
| title_short | Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates |
| title_sort | prime boost vaccination of mice and rhesus macaques with two novel adenovirus vectored covid 19 vaccine candidates |
| topic | COVID-19 vaccines simian adenovirus 23 vector human adenovirus 49 vector prime-boost vaccination mice and non-human primates |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2021.1931466 |
| work_keys_str_mv | AT shengxueluo primeboostvaccinationofmiceandrhesusmacaqueswithtwonoveladenovirusvectoredcovid19vaccinecandidates AT panlizhang primeboostvaccinationofmiceandrhesusmacaqueswithtwonoveladenovirusvectoredcovid19vaccinecandidates AT bochaoliu primeboostvaccinationofmiceandrhesusmacaqueswithtwonoveladenovirusvectoredcovid19vaccinecandidates AT chanyang primeboostvaccinationofmiceandrhesusmacaqueswithtwonoveladenovirusvectoredcovid19vaccinecandidates AT chaolanliang primeboostvaccinationofmiceandrhesusmacaqueswithtwonoveladenovirusvectoredcovid19vaccinecandidates AT qiwang primeboostvaccinationofmiceandrhesusmacaqueswithtwonoveladenovirusvectoredcovid19vaccinecandidates AT lingzhang primeboostvaccinationofmiceandrhesusmacaqueswithtwonoveladenovirusvectoredcovid19vaccinecandidates AT xitang primeboostvaccinationofmiceandrhesusmacaqueswithtwonoveladenovirusvectoredcovid19vaccinecandidates AT jinfengli primeboostvaccinationofmiceandrhesusmacaqueswithtwonoveladenovirusvectoredcovid19vaccinecandidates AT shuipinghou primeboostvaccinationofmiceandrhesusmacaqueswithtwonoveladenovirusvectoredcovid19vaccinecandidates AT jinfengzeng primeboostvaccinationofmiceandrhesusmacaqueswithtwonoveladenovirusvectoredcovid19vaccinecandidates AT yongshuifu primeboostvaccinationofmiceandrhesusmacaqueswithtwonoveladenovirusvectoredcovid19vaccinecandidates AT jeanpierreallain primeboostvaccinationofmiceandrhesusmacaqueswithtwonoveladenovirusvectoredcovid19vaccinecandidates AT tingtingli primeboostvaccinationofmiceandrhesusmacaqueswithtwonoveladenovirusvectoredcovid19vaccinecandidates AT yumingzhang primeboostvaccinationofmiceandrhesusmacaqueswithtwonoveladenovirusvectoredcovid19vaccinecandidates AT chengyaoli primeboostvaccinationofmiceandrhesusmacaqueswithtwonoveladenovirusvectoredcovid19vaccinecandidates |